The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
LGR5 rs17109924 to predict chemoresistance to 5FU-based chemotherapy in adjuvant colon cancer.
Armin Gerger
No relevant relationships to disclose
Sereina Herzog
No relevant relationships to disclose
Joanna Szkandera
No relevant relationships to disclose
Martin Pichler
No relevant relationships to disclose
Michael Stotz
No relevant relationships to disclose
Renate Schaberl-Moser
No relevant relationships to disclose
Hellmut Samonigg
No relevant relationships to disclose
Sigurd Lax
No relevant relationships to disclose
Gerhard Leitner
No relevant relationships to disclose
Wilfried Renner
No relevant relationships to disclose
Andrea Berghold
No relevant relationships to disclose
Heinz-Josef Lenz
No relevant relationships to disclose